Page 40 - Read Online
P. 40

Page 10                     Li et al. J Transl Genet Genom 2021;5:163-72  https://dx.doi.org/10.20517/jtgg.2021.22

               3.       Gregg JR, Zhang X, Chapin BF, et al. Adherence to the Mediterranean diet and grade group progression in localized prostate cancer:
                   an active surveillance cohort. Cancer 2021;127:720-8.  DOI  PubMed
               4.       Singh YN. Kava: an overview. J Ethnopharmacol 1992;37:13-45.  DOI  PubMed
               5.       Sarris J, Byrne GJ, Bousman CA, et al. Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-
                   controlled study. Aust N Z J Psychiatry 2020;54:288-97.  DOI  PubMed
               6.       Savage KM, Stough CK, Byrne GJ, et al. Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a
                   randomised controlled trial. Trials 2015;16:493.  DOI  PubMed  PMC
               7.       Smith K, Leiras C. The effectiveness and safety of Kava Kava for treating anxiety symptoms: a systematic review and analysis of
                   randomized clinical trials. Complement Ther Clin Pract 2018;33:107-17.  DOI  PubMed
               8.       Steiner GG. The correlation between cancer incidence and kava consumption. Hawaii Med J 2000;59:420-2.  PubMed
               9.       Li X, Liu Z, Xu X, et al. Kava components down-regulate expression of AR and AR splice variants and reduce growth in patient-
                   derived prostate cancer xenografts in mice. PLoS One 2012;7:e31213.  DOI  PubMed  PMC
               10.      Tang SN, Zhang J, Jiang P, et al. Gene expression signatures associated with suppression of TRAMP prostate carcinogenesis by a
                   kavalactone-rich kava fraction. Mol Carcinog 2016;55:2291-303.  DOI  PubMed  PMC
               11.      Liu Z, Xu X, Li X, et al. Kava chalcone, flavokawain A, inhibits urothelial tumorigenesis in the UPII-SV40T transgenic mouse model.
                   Cancer Prev Res (Phila) 2013;6:1365-75.  DOI  PubMed  PMC
               12.      Leitzman P, Narayanapillai SC, Balbo S, et al. Kava blocks 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung
                   tumorigenesis in association with reducing O6-methylguanine DNA adduct in A/J mice. Cancer Prev Res (Phila) 2014;7:86-96.  DOI
                   PubMed  PMC
               13.      Supramaniam  R,  O'Connell  D,  Tracey  E,  Sitas  F.  Cancer  in  New  South  Wales  Migrants  1991  to  2001.  Available  from:
                   https://www.cancercouncil.com.au/wp-content/uploads/2010/09/A-Pg-1-23-Intro.pdf. [Last accessed on 3 Jun 2021].
               14.      Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ. Global and regional estimates of cancer mortality and incidence by
                   site: II. Results for the global burden of disease 2000. BMC Cancer 2002;2:37.  DOI  PubMed  PMC
               15.      Li X, Pham V, Tippin M, et al. Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib
                   via Skp2 degradation. Cell Commun Signal 2019;17:25.  DOI  PubMed  PMC
               16.      Li X, Yokoyama NN, Zhang S, et al. Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of
                   tumorigenesis and cancer progression in the TRAMP transgenic mouse model. Oncotarget 2015;6:41809-24.  DOI  PubMed  PMC
               17.      Shappell SB, Thomas GV, Roberts RL, et al. Prostate pathology of genetically engineered mice: definitions and classification. The
                   consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee.
                   Cancer Res 2004;64:2270-305.  DOI  PubMed
               18.      Zheng YC, Duan YC, Ma JL, et al. Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit
                   gastric cancer cell growth, invasion, and migration. J Med Chem 2013;56:8543-60.  DOI  PubMed  PMC
               19.      Prinsloo D, van Dyk S, Petzer A, Petzer JP. Monoamine oxidase inhibition by kavalactones from kava (piper methysticum). Planta
                   Med 2019;85:1136-42.  DOI  PubMed
               20.      Wang K, Luo J, Yeh S, et al. The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant
                   prostate cancer. Nat Commun 2020;11:2689.  DOI  PubMed  PMC
               21.      Wu JB, Shao C, Li X, et al. Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis.  J Clin Invest
                   2014;124:2891-908.  DOI  PubMed  PMC
               22.      Zi X, Simoneau AR. Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of
                   Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice. Cancer Res
                   2005;65:3479-86.  DOI  PubMed
               23.      Pham V, Rendon R, Le VX, et al. Gartanin is a novel NEDDylation inhibitor for induction of Skp2 degradation, FBXW2 expression,
                   and autophagy. Mol Carcinog 2020;59:193-201.  DOI  PubMed  PMC
               24.      Zhao H, Nolley R, Chen Z, Reese SW, Peehl DM. Inhibition of monoamine oxidase A promotes secretory differentiation in basal
                   prostatic epithelial cells. Differentiation 2008;76:820-30.  DOI  PubMed  PMC
               25.      Sehrawat A, Gao L, Wang Y, et al. LSD1 activates a lethal prostate cancer gene network independently of its demethylase function.
                   Proc Natl Acad Sci U S A 2018;115:E4179-88.  DOI  PubMed  PMC
               26.      Metzger E, Wissmann M, Yin N, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent
                   transcription. Nature 2005;437:436-9.  DOI  PubMed
   35   36   37   38   39   40   41   42   43   44   45